NZ603399A - Pegylated c-peptide - Google Patents

Pegylated c-peptide

Info

Publication number
NZ603399A
NZ603399A NZ603399A NZ60339911A NZ603399A NZ 603399 A NZ603399 A NZ 603399A NZ 603399 A NZ603399 A NZ 603399A NZ 60339911 A NZ60339911 A NZ 60339911A NZ 603399 A NZ603399 A NZ 603399A
Authority
NZ
New Zealand
Prior art keywords
peptide
pegylated
treatment
disclosed
diabetes
Prior art date
Application number
NZ603399A
Other languages
English (en)
Inventor
James Callaway
Michelle Mazzoni
Sheri Barrack
Original Assignee
Cebix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cebix Inc filed Critical Cebix Inc
Publication of NZ603399A publication Critical patent/NZ603399A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
NZ603399A 2010-05-17 2011-05-17 Pegylated c-peptide NZ603399A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34529310P 2010-05-17 2010-05-17
US201161448402P 2011-03-02 2011-03-02
PCT/US2011/036858 WO2011146518A2 (en) 2010-05-17 2011-05-17 Pegylated c-peptide

Publications (1)

Publication Number Publication Date
NZ603399A true NZ603399A (en) 2014-09-26

Family

ID=44992295

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603399A NZ603399A (en) 2010-05-17 2011-05-17 Pegylated c-peptide

Country Status (9)

Country Link
US (2) US8927488B2 (OSRAM)
EP (1) EP2571896A4 (OSRAM)
JP (1) JP2013533217A (OSRAM)
KR (1) KR20130115086A (OSRAM)
CN (1) CN103119055A (OSRAM)
CA (1) CA2798518A1 (OSRAM)
MX (1) MX2012013375A (OSRAM)
NZ (1) NZ603399A (OSRAM)
WO (1) WO2011146518A2 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP3372617B1 (en) * 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX2012013375A (es) 2010-05-17 2013-04-11 Cebix Inc Peptido c pegilado.
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
EP2780030A4 (en) * 2011-11-17 2015-11-18 Cebix Ab PEGYLATED C-PEPTIDE
US20130288973A1 (en) * 2011-12-14 2013-10-31 Edmund Burke Decellularized small particle tissue
US9988433B2 (en) * 2013-03-14 2018-06-05 Mosaic Biosciences, Inc. Covalent modification of biological macromolecules
WO2013116791A1 (en) 2012-02-02 2013-08-08 Mosaic Biosciences, Inc. Biomaterials for delivery of blood extracts and methods of using same
US20150087586A1 (en) * 2012-03-29 2015-03-26 Cebix, Inc. Pegylated c-peptide
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
BR122019026637B1 (pt) * 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
AU2014328458B2 (en) * 2013-09-24 2020-03-12 Allergan Pharmaceuticals International Limited Method of extracting protein
RU2017131285A (ru) * 2015-02-09 2019-03-11 Мозеик Байосайенсиз, Инк. Биоразлагаемые тиол-ен-полимеры и способы их получения
US10335492B2 (en) * 2015-03-03 2019-07-02 Nansha Biologics (Hong Kong) Limited Increasing serum half-life of human IL-11 variants by N-terminal branched PEGylation
CA2979397A1 (en) 2015-03-12 2016-09-15 Board Of Trustees Of Michigan State University Compositions and methods for measuring c-peptide binding and diagnosing immune-mediated diseases
SG10202008963QA (en) * 2015-09-18 2020-10-29 Univ Miyazaki Long-acting adrenomedullin derivative
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
ES2894629T3 (es) 2017-06-16 2022-02-15 Zealand Pharma As Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
JP7058857B2 (ja) * 2017-08-30 2022-04-25 クラシエホームプロダクツ株式会社 毛髪タンパク質の水との相互作用測定方法
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
EP3687578B1 (en) * 2017-09-28 2023-12-27 The Regents of the University of California Polyion complex polypeptide hydrogels and uses thereof
US11357861B2 (en) 2017-09-29 2022-06-14 Hanmi Pharm. Co., Ltd Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
EP4321220B1 (en) * 2017-12-01 2025-10-29 CSL Behring LLC A1at for treating acute graft versus host disease after hematopoeitic cell transplantation
JPWO2019107566A1 (ja) 2017-12-01 2020-12-03 株式会社ステムリム 外胚葉性間葉系幹細胞およびその製造方法
AU2019268410B2 (en) * 2018-05-16 2025-01-02 Csl Limited Soluble complement receptor type 1 variants and uses thereof
EP3628682A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CN113423466B (zh) * 2018-10-25 2025-04-25 国立大学法人大阪大学 软骨病症的治疗剂
BR112021008098A2 (pt) 2018-11-15 2021-08-10 Quantum-Si Incorporated métodos e composições para o sequenciamento de proteínas
US20220177704A1 (en) * 2019-03-27 2022-06-09 The Regents Of Theuniversity Of California Mixtures of synthetic copolypeptide hydrogels
CN113677736B (zh) * 2019-03-29 2024-08-02 日油株式会社 分支型分解性聚乙二醇衍生物
EP3950703A4 (en) 2019-03-29 2023-01-04 NOF Corporation Branched degradable polyethylene glycol binder
CN111939244B (zh) * 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
KR102456958B1 (ko) 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
US12090206B2 (en) 2020-04-23 2024-09-17 The Regents Of The University Of California Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels
WO2021236983A2 (en) * 2020-05-20 2021-11-25 Quantum-Si Incorporated Methods and compositions for protein sequencing
CN114137094A (zh) * 2020-09-03 2022-03-04 北京渼颜空间生物医药有限公司 一种聚左旋乳酸中有关物质的检测方法
US20220401525A1 (en) * 2021-06-16 2022-12-22 Biocell Technology, Llc Use of collagen compositions for increasing telomere length
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW17482A1 (en) * 1981-08-27 1982-11-17 Lilly Co Eli Pharmaceutical formulations comprising human insulin and human c-peptide
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FR2686759B1 (fr) 1992-01-29 1994-04-22 Sgs Thomson Microelectronics Dispositif de regulation de puissance pour un haut-parleur de poste de telephone pendant une sonnerie .
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
GB9716790D0 (en) 1997-08-07 1997-10-15 Creative Peptides Sweden Ab Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
ES2222689T3 (es) 1998-03-12 2005-02-01 Nektar Therapeutics Al, Corporation Derivados del polietilenglicol con grupos reactivos proximales.
DK1140145T4 (da) * 1999-01-14 2019-07-22 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ATE446971T1 (de) 2001-09-07 2009-11-15 Biocon Ltd Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
JP4758608B2 (ja) * 2001-11-07 2011-08-31 ネクター セラピューティックス 分枝ポリマーおよびそれらの結合体
RS53104A (sr) * 2001-11-20 2006-10-27 Pharmacia Corporation Hemijski modifikovani konjugati humanog hormona rasta
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
JP4764630B2 (ja) 2002-09-09 2011-09-07 ネクター セラピューティックス 水溶性ポリマーアルカナール
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
PT2644206T (pt) 2003-05-23 2019-07-10 Nektar Therapeutics Derivados de peg contendo duas cadeias de peg
US20050074425A1 (en) 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
KR20120073370A (ko) * 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
CA2563176A1 (en) * 2004-04-22 2005-11-10 Regado Biosciences, Inc. Improved modulators of coagulation factors
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
US9085659B2 (en) 2004-05-03 2015-07-21 Nektar Therapeutics Polymer derivatives comprising an imide branching point
GB0412174D0 (en) * 2004-06-01 2004-06-30 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
EP1850878A2 (en) * 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
ATE524509T1 (de) 2005-07-18 2011-09-15 Nektar Therapeutics Verzweigte funktionalisierte polymere unter verwendung von verzweigten polyolen als kernen
GB0601950D0 (en) 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
JP5550338B2 (ja) * 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
RU2007137048A (ru) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете
WO2009117410A2 (en) 2008-03-17 2009-09-24 Board Of Regents, The University Of Texas System Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
US20110190192A1 (en) 2009-12-15 2011-08-04 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
MX2012013375A (es) 2010-05-17 2013-04-11 Cebix Inc Peptido c pegilado.

Also Published As

Publication number Publication date
WO2011146518A9 (en) 2012-04-19
EP2571896A2 (en) 2013-03-27
EP2571896A4 (en) 2014-01-08
KR20130115086A (ko) 2013-10-21
US8691755B2 (en) 2014-04-08
CA2798518A1 (en) 2011-11-24
WO2011146518A2 (en) 2011-11-24
US8927488B2 (en) 2015-01-06
US20120220542A1 (en) 2012-08-30
JP2013533217A (ja) 2013-08-22
WO2011146518A3 (en) 2012-03-08
MX2012013375A (es) 2013-04-11
CN103119055A (zh) 2013-05-22
US20120178676A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
NZ603399A (en) Pegylated c-peptide
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
EP2316510A3 (en) Shield apparatuses and methods for storing syringe assemblies and needle assemblies
MX354705B (es) Analogos de glucagon novedosos.
MX353955B (es) Hebras de acido hialuronico reticulado y metodos de uso de las mismas.
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
NZ603319A (en) Diabetes therapy
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX349642B (es) Artículo absorbente.
MX347501B (es) Artículo absorbente.
MX349641B (es) Articulo absorbente.
NZ626954A (en) Combination therapy of antibodies against human csf-1r and uses thereof
WO2011020319A8 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
PH12012501895A1 (en) Long-acting formulations of insulins
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
WO2015105981A3 (en) Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment
NZ702169A (en) The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
WO2011146926A3 (en) Systems and methods for treatment of sleep apnea
GEP201706716B (en) Optimised subcutaneous therapeutic agents
MX2013008530A (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
WO2012054607A3 (en) Treatment of diabetes using g-csf and hyperbaric oxygen
MX2019002657A (es) Combinaciones con un peptido con esqueleto ciclado.
MX366993B (es) Combinaciones con un peptido ciclado con la estructura de la base.
MX347502B (es) Artículo absorbente.

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed